Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by U.S. FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  C1 inhibitor therapy has been used acutely for more than 35 years in Europe to treat patients with C1 inhibitor deficiency.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials.

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consu
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... CHICAGO, Ill. , June 1, 2015  AbbVie ... 2015 Healthcare Conference on Thursday, June 4, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:6/1/2015)... BOSTON , June 1, 2015 Symbiotix ... a $2.3 million Phase 2 Small Business Technology Transfer ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... is developing a novel class of molecular therapeutics ... lead clinical candidate, Polysaccharide A (PSA), is the first ...
(Date:6/1/2015)... N.J. , June 1, 2015  Elusys ... and Drug Administration (FDA) has accepted for filing ... Anthim® (obiltoxaximab) for the treatment and prevention of ... submitted on March 20, 2015. Anthim is a ... Stockpile, the U.S. government,s repository of critical medical ...
Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... NEW YORK, April 18, 2012 Financial executives in ... excise tax and the burden of its related compliance ... bottom lines, according to a survey conducted by KPMG ... of respondents said their companies are already contemplating actions ...
... NEW YORK, April 18, 2012 ... initiates coverage on Pacira Pharmaceuticals ... price target $18.00. ... is a member of the ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:6/1/2015)... Ore. (PRWEB) June 01, 2015 ... (AHIP) announced today a new, interactive Affordable Care ... large employers. The course, called “Affordable Care Act ... professionals with the strategic and consultative insights necessary ... as they navigate the impacts of the ACA. ...
(Date:6/1/2015)... a leading web-base electronic healthcare software (EHR) is providing ... Louisiana. The entrepreneurial trio behind Sharenote, will travel to ... with the tools and resources to monitor key performance ... , Find out why Sharenote is the EHR ... 250 practices. , Four Day Schedule , ...
(Date:6/1/2015)... 2015 KC and Monica Craichy, Founders ... the best superfood products in the world ... Texas. , "Monica and I are excited to ... distributing Living Fuel Super Meals - SuperBerry®, SuperGreens and ... in Texas," KC Craichy said. "We have attempted to ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 More than 22 ... summer months when school is out and they lose access ... Month and America’s dairy farmers and milk companies are on ... need with The Great American Milk Drive. , In ... provided in the school cafeteria for the bulk of their ...
(Date:6/1/2015)... Northridge dentist , Dr. Michel Elyson, ... promotion on Invisalign for a limited time only. With ... to $3,700. Patients can find out about their candidacy ... the extent of correction they need. This promotion expires ... any other offer. , Invisalign has continued to ...
Breaking Medicine News(10 mins):Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2
... menstrual cycle into account when booking exam may cut need ... News) -- Using a blood test to pinpoint the optimal ... cycles could reduce the need for repeat scans, U.S. researchers ... scans during the follicular phase (days 3 to14) of the ...
... of successful events organised last year, a second Joint ... (ESC) and the European Association for the Study of ... organisations in Europe, will be held from 27-29 November ... Guangzhou. The theme is the Optimal Management of Diabetes, ...
... YORK, Nov. 20 Mallika Chopra, healthy living expert and ... natural stress relief products in the US, are teaming up ... program kicks off with advice from Chopra, to be posted ... the holidays without the stress or foreboding that typically comes ...
... and palliation in patients with pancreatic neuroendocrine tumors (PNTs), ... therapy, according to a largest of its kind study ... Journal of Radiation Oncology*Biology*Physics , the official journal of ... is a very rare form of pancreatic cancer that ...
... every 2 years or more, not annually, , FRIDAY, Nov. ... week, medical experts are revising the advice given women on ... should get their first screening for cervical cancer -- including ... in guidelines released Nov. 20 by the American College of ...
... 20 New data released today by Quest ... provider of employment-related drug testing services, reveal that drug testing ... general U.S. workforce has tracked sharp downward trends in cocaine ... 2009 that mirror similar drops shown by urine testing. Data ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:ESC to give talks on diabetes in 3 cities in China 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3Health News:Rare pancreatic cancer patients may live longer when treated with radiation therapy 2Health News:New Pap Test Guidelines: Start Later, Have Fewer 2Health News:New Pap Test Guidelines: Start Later, Have Fewer 3Health News:New Pap Test Guidelines: Start Later, Have Fewer 4Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 2Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 3Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 4Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 5Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 6Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 7Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 8Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 9Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 10
The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
... Detect™ IgM Capture ELISA is for the ... WNV recombinant antigens (WNRA) in serum as ... of West Nile virus infection in patients ... results must be confirmed by Plaque Reduction ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: